Direct links on RSV from stakeholders
Domus Medica
Médecins généralistes francophones
- Information stop bronchiolite- FR
- conditions de remboursement- FR
- Protégéz votre bébé de la bronchiolite
ONE
- VIRUS RESPIRATOIRES ET BRONCHIOLITE : NOUVELLE POSSIBILITÉ DE PROTECTION POUR VOTRE NOURRISSON
- https://www.vaccination-info.be/maladie/vrs/
- feuillet immunisation
BCFI
- Beschermt nirsevimab zuigelingen tegen ziekenhuisopname door RSV?
- Le nirsévimab protège-t-il le nourrisson contre l’hospitalisation due au VRS ?
- Reimbursement form
Sanofi
- Vaccin info FR
- Vaccin info NL
- Hospital Pharmacy: reservation form Beyfortus
- information availability Beyfortus
Sciensano
FAQ
What about infants under 13 months born before April 1, 2024?
These are NOT eligible for reimbursement of nirsevimab (Beyfortus°), even if they are premature and may not yet have been exposed to RSV.
Reimbursement for palivizumab (Synagis°) remains available for prematurely born children who meet the criteria (criteria NL and criteria FR). Stock is available.
What about infants under 13 months whose mothers received the Abrysvo® vaccine between January 2024 and March 2024?
for these cases, no reimbursement for nirsevimab (Beyfortus°) is provided.
Can a CIVARS approval be revoked?
Yes, this is possible. This is a legal grey area.
What about vulnerable children without a Belgian National Registry Number?
A Belgian National Registry Number is an absolute requirement. Therefore, only being registered with a Belgian health insurance is insufficient without the Belgian National Registry Number! Each case should be treated individually with the relevant authorities (Fedasil, OCMW, etc.).